Based upon the data presented above, we propose that the prominent impact of hepatic Hif2a deficiency on Mn excess, Epo excess, polycythemia, and hepatic gene expression warrants an investigation into the long-term treatment of Slc30a10–/– mice with agents that inhibit Hif2a expression and/or activity. The gene discussed is EPAS1; the disease is polycythemia.